NCT05326308View on ClinicalTrials.gov

Zanubrutinib in Patients With Waldenström's Macroglobulinemia, Chronic Lymphocytic Leukemia, Marginal Zone Lymphoma and Follicular Lymphoma

RecruitingOBSERVATIONAL
Enrollment

705

Participants

Timeline

Start Date

April 26, 2022

Primary Completion Date

August 31, 2028

Study Completion Date

August 31, 2028

Conditions
Waldenström's MacroglobulinemiaChronic Lymphocytic LeukemiaMarginal Zone LymphomaFollicular Lymphoma
Interventions
DRUG

Zanubrutinib

according to the Summary of Product Characteristics (SmPC).

DRUG

Obinutuzumab

according to the Summary of Product Characteristics (SmPC).

Trial Locations (2)

A-5020

RECRUITING

Universitätsklinikum Salzburg, Klinik für Innere Medizin III, Salzburg

D-23562

RECRUITING

Lübecker Onkologische Schwerpunktpraxis, Lübeck

All Listed Sponsors
collaborator

BeOne Medicines I GmbH Switzerland

UNKNOWN

lead

iOMEDICO AG

INDUSTRY

NCT05326308 - Zanubrutinib in Patients With Waldenström's Macroglobulinemia, Chronic Lymphocytic Leukemia, Marginal Zone Lymphoma and Follicular Lymphoma | Biotech Hunter | Biotech Hunter